Company intelligence / Profile preview

On Target Laboratories

West Lafayette, Indiana, United Statesontargetlabs.com ↗

Ownership: Private
Development stage: Commercial

Overview

CYTALUX received FDA approval for ovarian cancer in November 2021 and a supplemental New Drug Application for lung cancer in December 2022. The imaging agent helps surgeons visually identify additional cancerous tissue during surgery.

Therapeutic areas: Oncology
Modalities: Intraoperative molecular imaging agents
Industry: Biotech

Drug pipeline

4 assets

pafolacianine

Approved

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on On Target Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on On Target Laboratories.

Explore the full profile